Skip To Main Content
SponsoredBy BB Biotech on Muck Rack

SponsoredBy BB Biotech

As seen in: Portfolio Adviser
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with SponsoredBy BB

Contact SponsoredBy BB, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

BB Biotech holds steady in the second quarter

|
By SponsoredBy BB Biotech, BB Biotech, Ian Fendley
| Portfolio Adviser Verified
Major headwinds caused by various factors such as the talk of the US federal government imposing drug price controls and the general impression that the bull market is on its last leg weighed on investor sentiment in the healthcare sector during the second quarter. BB Biotech shares were not completely immune to these developments and delivered a return of 1.2% in EUR for the second quarter and 8.2% for the first half of 2018.
Open in Who Shared Issue with article?

Biotech in the fight against cancer

|
By BB Biotech, Ian Fendley, SponsoredBy BB Biotech
| Portfolio Adviser Verified
Big players in the healthcare sector are desperate to differentiate their approved ‘checkpoint inhibitors’ (a drug that unleashes an immune system attack on cancer cells) by combining their use with conventional chemotherapy or other new drugs. Biotechnology firms are developing many of these next-generation combination agents as well as continuing to strengthen their positions in treatments for more niche medical problems. This makes for an interesting area for investors.
Open in Who Shared Issue with article?
See all 2 articles